Mexico Nuclear Imaging Market

Mexico Nuclear Imaging Market Analysis

Mexico’s nuclear medicine market size stands at USD 297.1 million in 2025 and is forecast to reach USD 389.0 million by 2030, advancing at a 5.54% CAGR, underscoring sustained investment momentum in diagnostic and therapeutic imaging technologies. Consistent public-sector spending, a 30.2% IMSS-Bienestar budget expansion and the opening of 9 new hospitals in 2025 collectively signal a near-term lift in equipment procurement. Simultaneously, the country’s 90% import reliance on medical devices keeps Mexico firmly integrated into U.S. and Asian supply chains, creating a receptive channel for radiopharmaceutical and hybrid-scanner vendors. Oncology and cardiology remain the primary volume drivers as national cancer incidence accelerates and new PET tracers for coronary artery disease arrive, pulling hybrid SPECT/CT and PET/CT upgrades into hospital planning cycles. Private diagnostic centers are scaling faster than any other care-delivery node, encouraged by healthcare privatization, M&A activity and attractive reimbursement for specialized services.

Mexico Nuclear Imaging Market Trends and Insights

Rising Cancer & Cardiovascular Incidence

Cancer prevalence is climbing in Mexico, yet only 5% of facilities currently deliver oncology care, prompting hospitals to adopt integrated nuclear medicine suites that close diagnostic gaps. Colorectal, lung and prostate cancers present the highest unmet imaging demand, driving uptake of Technetium-99m SPECT studies and PSMA-targeted PET scans. Domestic radiopharmaceutical development, exemplified by 177Lu-iPSMA and 177Lu-DOTATOC, is extending survival in metastatic disease while lowering import exposure. Cardiovascular disease likewise fuels the nuclear medicine market; GE HealthCare’s flurpiridaz F-18 tracer offers longer half-life logistics advantages and will be launched nationally in early 2025. These disease-burden dynamics collectively add 1.2 percentage points to the CAGR forecast of the nuclear medicine market.

Public-Sector Imaging Capex (INSABI, IMSS)

President Claudia Sheinbaum’s 2025 budget lifts IMSS-Bienestar funding to MXN 174.6 billion, earmarking resources for diagnostic imaging modernization. Nine new hospitals and six family medicine units opening in 2025 will each include nuclear medicine departments, immediately boosting capital equipment tender volumes. INSABI’s broader mandate for universal coverage is translating into procurement pipelines for hybrid scanners, hot-lab infrastructure and cold kits. While drug supply chain snags persist, the government’s MXN 30 billion savings strategy incentivizes vendors that bundle service contracts with equipment, enhancing lifecycle affordability. Collectively, public-sector capex contributes a +0.8% lift to the nuclear medicine market CAGR.

Hybrid SPECT/CT & PET/CT Upgrades

Clinicians increasingly require metabolic-plus-anatomic co-localization for treatment planning, triggering a replacement wave toward hybrid modalities. Canon Medical and Hermes Medical’s workflow-optimization alliance illustrates vendor emphasis on software-guided efficiency that Mexican providers are keen to adopt. GE HealthCare’s seven-year AI imaging pact with Sutter Health underscores integrated lifecycle offerings that appeal to local private groups. Siemens Healthineers’ USD 16.2 billion oncology-imaging pipeline further supports continuous feature migration to Mexican fleets. The transition adds a 0.7 percentage-point tailwind to CAGR as facilities retire single-head gamma cameras in favor of dual-head SPECT/CT and time-of-flight PET/CT.

Private Nuclear-Pharmacy Build-out

New central radio-pharmacies in Guadalajara and Monterrey are designed to compound F-18 and Ga-68 tracers, shortening delivery windows and stabilizing supply for remote centers. Operators are adopting lean manufacturing and automated synthesis to meet GMP and COFEPRIS standards, lowering dose unit costs against imported supplies. Investment appetite is buoyed by an emerging therapeutic pipeline that requires on-site or near-site radiochemistry. Over the long term, these private installations are forecast to add 0.5 percentage points to the nuclear medicine market CAGR.

High Equipment & Maintenance Costs

A PET/CT suite costs USD 2–4 million upfront and 8–12% of purchase value annually for service contracts, straining capital budgets where public health outlays equal only 3.3% of GDP. COFEPRIS entry fees of USD 5,000–10,000 and approval timelines of up to 18 months extend payback periods for vendors, further inflating list prices. Tariffs on imported scanner subassemblies have also lifted acquisition costs for Siemens and GE units manufactured partially in Mexico, limiting diffusion into secondary cities. Consequently, this restraint subtracts 1.1 percentage points from the nuclear medicine market CAGR.

Limited Reimbursement for Advanced Scans

Fragmented payer policies across IMSS, ISSSTE and private insurers result in uneven coverage for PET-based oncology staging and cardiac perfusion studies, dampening patient volumes. Universal-coverage reforms prioritize preventive and primary care, directing less funding toward high-cost diagnostics. Although niche insurance offerings like Oncosalud are emerging, uptake remains limited to higher-income populations. Payment uncertainty deducts 0.9 percentage points from CAGR projections.

Segment Analysis

By Product: Radioisotopes Sustain Leadership and Momentum

Radioisotopes recorded a 62.23% nuclear medicine market share in 2024 and are projected to outpace equipment at a 5.89% CAGR through 2030, reinforcing their centrality to clinical volume growth. The nuclear medicine market size associated with Technetium-99m SPECT tracers alone exceeded USD 185 million in 2024, validating the segment’s revenue heft. PET isotopes are climbing fastest as cardiology adopts flurpiridaz F-18 and oncology diversifies into Ga-68 and Cu-64 agents. Local production of 177Lu-labeled therapeutics underscores Mexico’s emerging capacity in theranostics, positioning domestic suppliers to lower import dependence and hedge Mo-99 supply risk.

Equipment demand trails but benefits from hybrid-system upgrades and AI-driven workflow expectations. Hospitals allocate higher capex to SPECT/CT replacements, while private groups selectively deploy PET/CT in large metros. PET/MRI remains research-oriented due to total cost of ownership, yet niche uptake in university hospitals aids translational trials. As COFEPRIS implements NOM-137-SSA1-2024 labeling rules, vendors with compliant lifecycle support gain an edge. Over the forecast horizon, the nuclear medicine market will continue to see radioisotope revenue dominate, yet the equipment refresh curve provides suppliers with recurring placement opportunities.

By Application: SPECT Commands Volume, PET Generates Velocity

SPECT accounted for 70.34% of nuclear medicine market share in 2024, anchored by myocardial perfusion, thyroid and bone scans that collectively drive daily throughput. Cardiology SPECT retains reimbursement favorability and broad tracer availability, whereas thyroid imaging maintains steady demand via I-123 agents. Nevertheless, PET’s 6.00% CAGR projects that oncology staging, particularly PSMA-guided prostate workflows, will erode SPECT’s dominance. The nuclear medicine market size attributed to PET procedures is expected to exceed USD 144 million by 2030, aided by flurpiridaz’s cardiac indication and rising pediatric oncology adoption.

Thyroid and infection imaging remain SPECT strongholds, yet advances in total-body PET are setting new diagnostic baselines in pediatric solid tumors. Dual-platform hospitals are integrating both modalities to tailor care pathways, underscoring hybrid service positioning. PET’s superior resolution, reduced scan times via AI-assisted reconstruction and new tracer launches create a compelling utilization curve, especially in private diagnostic centers where equipment amortization is volume driven.

By End User: Hospitals Maintain Scale Advantage While Diagnostic Centers Accelerate

Hospitals generated 53.82% of nuclear medicine market size in 2024, leveraging embedded inpatient and surgical pathways that naturally propel imaging referrals. IMSS’s network expansion will reinforce hospital share by adding installed base capacity in eight states. Yet, diagnostic centers exhibit 6.11% CAGR as private equity backs standalone facilities equipped with PET/CT, SPECT/CT and on-site radiopharmacy, lowering patient wait times and enhancing convenience.

Academic and research institutes contribute specialist protocols and technologist training, indirectly supporting market expansion by enhancing clinical confidence and workforce availability. Workforce shortages, however, compel rural hospitals to refer complex cases to urban diagnostic centers, perpetuating the growth differential. Partnerships between hospitals and mobile imaging providers are emerging to bridge service gaps, enabling smaller facilities to host periodic PET days without full capex exposure.

Geography Analysis

Mexico’s nuclear medicine market size remains heavily concentrated in the center of the country, where Mexico City and surrounding states account for 53.82% of hospital activity in 2024. The Instituto Nacional de Cancerología in Mexico City shapes national protocols by comparing 99mTc-iPSMA SPECT/CT with 18F-PSMA-1007 PET/CT for prostate-cancer staging. Médica Sur’s integrated PET-CT center underscores the capital’s role as a referral hub for domestic and international patients. Regulatory proximity to COFEPRIS headquarters further accelerates technology adoption in the central region.

Guadalajara anchors western growth as private nuclear-pharmacy investment and Pacific trade routes attract medical-tourism volumes. Monterrey and the northeastern industrial corridor demand occupational-health imaging that supports the country’s manufacturing workforce. Northern border hospitals exploit geographic closeness to U.S. cyclotrons for rapid Mo-99 and F-18 deliveries, although periodic customs delays still disrupt scheduling reliability. IMSS will equip the new Hospital General de Zona in Tuxtla Gutiérrez with a hybrid scanner in 2025, marking the first full-service nuclear-medicine unit in Chiapas.

Southern and southeastern states remain underserved, yet President Sheinbaum has earmarked MXN 174.6 billion for IMSS-Bienestar upgrades that prioritize these regions. The Yucatán Peninsula and Gulf Coast now attract private funds as tourism growth demands advanced oncology diagnostics. Mobile PET-CT programs and tele-consultations are emerging stop-gaps while permanent sites are built. Pacific-coast states capitalize on international oncology referrals that rely on theranostic services. Uniform COFEPRIS quality rules apply nationwide, but high compliance costs continue to favor established operators with local regulatory teams.

Competitive Landscape

Mexico’s nuclear medicine market displays moderate concentration with GE HealthCare, Siemens Healthineers and Philips Healthcare leading hybrid-scanner installations, while Curium, Novartis and Telix dominate radiopharmaceutical portfolios. GE’s acquisition of Nihon Medi-Physics strengthens its vertical integration, enabling bundled isotope-plus-equipment deals that appeal to IMSS tender committees. Siemens is funneling USD 16.2 billion into oncology imaging R&D, which will filter into the Mexican installed base via time-of-flight detectors and AI reconstruction. Philips leverages Mexico’s established electromedical device clusters, ensuring proximity service and lower logistics costs.

Curium’s March 2025 purchase of Monrol scales Lutetium-177 output, positioning the company to supply Mexican theranostic trials and hospital therapies. Novartis’ U.S. radioligand factories add redundancy to Lu-177 and Ac-225 supply chains, advantageous for local wholesalers targeting stable therapeutic dose access. Telix advances diagnostic-therapeutic convergence through PSMA- and CA-IX-targeted tracers, raising competitive pressure in precision oncology niches. Meanwhile, Canon Medical and United Imaging harness cost-effective hardware to penetrate value-sensitive tenders.

COFEPRIS approval windows and labeling mandates generally favor incumbents with embedded regulatory teams, sustaining moderate market concentration. Still, private nuclear-pharmacy entrants and mobile imaging startups inject competitive vigor, keeping pricing dynamics fluid. Vendor alliances around AI workflow, total-body PET and pediatric oncology will shape differentiation over the forecast period.